NASDAQ · ONCY
Healthcare · Biotechnology
$0.86
Down-$0.01 (-0.67%)
Updated Aug 27, 2026, 1:03 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ONCY closed at $0.86 after 21 trading sessions, up 13.84% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 26, 2026 | $0.8598 | $0.8657 | $0.8401 | $0.8556 | 410.86K |
| Aug 25, 2026 | $0.85 | $0.87 | $0.8401 | $0.8614 | 777.41K |
| Aug 24, 2026 | $0.8499 | $0.85 | $0.8039 | $0.8441 | 488.77K |
| Aug 21, 2026 | $0.80 | $0.8492 | $0.80 | $0.8431 | 545.01K |
| Aug 20, 2026 | $0.8264 | $0.8266 | $0.7901 | $0.8017 | 682.04K |
| Aug 19, 2026 | $0.841 | $0.86 | $0.825 | $0.831 | 608.72K |
| Aug 18, 2026 | $0.82 | $0.856 | $0.82 | $0.8448 | 798.71K |
| Aug 17, 2026 | $0.8375 | $0.8488 | $0.8123 | $0.8227 | 523.15K |
| Aug 14, 2026 | $0.80 | $0.846 | $0.7832 | $0.834 | 1.13M |
| Aug 13, 2026 | $0.84 | $0.84 | $0.80 | $0.80 | 587.3K |
| Aug 12, 2026 | $0.803 | $0.828 | $0.7939 | $0.8237 | 716.02K |
| Aug 11, 2026 | $0.80 | $0.825 | $0.78 | $0.82 | 672.97K |
| Aug 10, 2026 | $0.796 | $0.8099 | $0.7601 | $0.8028 | 813.61K |
| Aug 7, 2026 | $0.8045 | $0.82 | $0.7929 | $0.8025 | 571.29K |
| Aug 6, 2026 | $0.786 | $0.8179 | $0.786 | $0.8006 | 555.33K |
| Aug 5, 2026 | $0.8036 | $0.8099 | $0.782 | $0.7972 | 431.72K |
| Aug 4, 2026 | $0.795 | $0.82 | $0.78 | $0.8105 | 578.64K |
| Aug 3, 2026 | $0.7533 | $0.7917 | $0.75 | $0.775 | 747.03K |
| Jul 31, 2026 | $0.765 | $0.7661 | $0.7371 | $0.7533 | 834.86K |
| Jul 30, 2026 | $0.7587 | $0.766 | $0.7301 | $0.753 | 998.4K |
| Jul 29, 2026 | $0.78 | $0.7898 | $0.745 | $0.7516 | 907.7K |
The latest Smart Investors Daily articles mentioning ONCY.
ONCY research
Company profile and research snapshot.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2025 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
| Aug 11, 2025 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
| Aug 8, 2025 | JONES TRADING | Hold | — |
| Aug 7, 2025 | JONES TRADING | Hold | — |
| Jul 9, 2025 | LEEDE JONES GABLE | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and lowers the price target from $10 to $5.
Yahoo · Aug 19, 2026
Oncolytics Biotech has received FDA feedback supporting a potential pivotal expansion of its REO 033 colorectal cancer trial.
Yahoo · Aug 18, 2026
FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company develo
Benzinga · Aug 18, 2026
Company received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the design of a potential pivotal Part B expansion of REO 033, the Company’s ongoing randomized study evaluating
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ONCY.
